OncologyNCT04624165
Patient Perspective of Telemedicine in Gynecology Oncology
An observational study of Oncology, run by TriHealth Inc. at 1 site in United States.
Trial summary
Research question: do patients in a gynecologic oncology practice value the use of telemedicine as an adjunct to in-person visits and in what circumstances might patients not find these visits to be sufficient? Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Oncology
- What is being tested?
- Survey
- How many people
- 116 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Jan 2021to 24 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: o Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.
- Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.
Trial locations and contacts
1 site in 1 country.
United States1 site
TriHealth - Good Samaritan and Bethesda North Hospitals
Cincinnati, Ohio, 45220
About this study
Research question: do patients in a gynecologic oncology practice value the use of telemedicine as an adjunct to in-person visits and in what circumstances might patients not find these visits to be sufficient?
Read the detailed description
In the United States, 14.8 million women live greater than 50 miles away from the closest gynecology oncologist underscoring the need for increased implementation of telemedicine. In consideration of the COVID-19 outbreak, recommendations were made to organize goals of therapy by prioritizing curative intent and utilizing telemedicine to manage current therapies. Research regarding telemedicine, its benefits, and patient perspectives in other specialties has been reported, however there appears to be a dearth of information in the field of gynecologic oncology. Our study aims to seek patients' perspective of telemedicine and whether implementation for extended office visits, teleconsultations and more are feasible and valuable to them.
- Conditions
- Oncology
- Being tested
- Survey
- Keywords
- Telemedicine
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
- We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient's perspective on telemedicine on a Likert Scale
Patient's perspective on telemedicine on a Likert Scale
Measured: Through survey completion, an average of 15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2020
- Study start21 Jan 2021
- Primary completion30 Jul 2021
- Study completion24 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OncologyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 116 participants (actual)
Sponsor and investigators
- Lead sponsor
- TriHealth Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Robert Neff, MD, Principal investigator, TriHealth Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04624165
- Sponsor's protocol ID
- 20-092
- Status last verified
- Aug 2023
- First submitted
- 26 Oct 2020
- Last updated
- 8 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Perspective of Telemedicine in Gynecology Oncology
- ClinicalTrials.gov ID
- NCT04624165
- Acronym / sponsor ID
- 20-092
- Conditions
- Oncology
- Keywords
- Telemedicine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 116 participants (actual)
- Lead sponsor
- TriHealth Inc.University, hospital or other
- Study start
- 21 Jan 2021 (actual)
- Primary completion
- 30 Jul 2021 (actual)
- Study completion
- 24 Oct 2022 (actual)
- First posted
- 10 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research question: do patients in a gynecologic oncology practice value the use of telemedicine as an adjunct to in-person visits and in what circumstances might patients not find these visits to be sufficient?
Detailed description
In the United States, 14.8 million women live greater than 50 miles away from the closest gynecology oncologist underscoring the need for increased implementation of telemedicine. In consideration of the COVID-19 outbreak, recommendations were made to organize goals of therapy by prioritizing curative intent and utilizing telemedicine to manage current therapies. Research regarding telemedicine, its benefits, and patient perspectives in other specialties has been reported, however there appears to be a dearth of information in the field of gynecologic oncology. Our study aims to seek patients' perspective of telemedicine and whether implementation for extended office visits, teleconsultations and more are feasible and valuable to them.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- o Eligible patients would be at least 18 years of age, and currently being treated by one of the providers within the gynecologic oncology group.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surveyo We plan to hand out copies of a survey to examine patient's perspective on telemedicine. | Other | – |
Primary outcome
Patient's perspective on telemedicine on a Likert Scale
Time frame: Through survey completion, an average of 15 minutes
Patient's perspective on telemedicine on a Likert Scale
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2023.
- Individual participant dataSharing planned: No
Related trials for Oncology
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Neff, MD principal investigator
TriHealth Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oncology, run by TriHealth Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient's perspective on telemedicine on a Likert Scale (time frame: Through survey completion, an average of 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2023.